A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
This research study is for people aged 40 to 80 living with Chronic Obstructive Pulmonary Disease (COPD) who are also at a higher risk of heart or lung problems. It aims to see how well a new 'triple therapy' inhaler, called BGF MDI, works compared to a standard 'dual therapy' inhaler, called GFF MDI. Both inhalers contain medicines that help open up the airways. Researchers want to find out if the new inhaler can lead to better health outcomes for participants, especially concerning their heart and lung health. It's a large study where some people will get the new inhaler and others the standard one, without knowing which they're receiving.
At a glance
What is this study about?
This study is about Chronic Obstructive Pulmonary Disease (COPD), a lung condition that makes it hard to breathe. If you have COPD and are also at a higher risk of developing heart or other lung-related problems, this study might be relevant to you. The main goal is to compare a new type of inhaler (called 'triple therapy') with one that's already used (called 'dual therapy'). Both inhalers contain different combinations of medicines designed to help your breathing.
The 'triple therapy' inhaler being tested combines three active ingredients: budesonide, glycopyrronium, and formoterol fumarate. The 'dual therapy' inhaler contains glycopyrronium and formoterol fumarate. Researchers want to understand if the triple therapy inhaler can better protect your heart and lungs and improve your overall health compared to the dual therapy.
By taking part, you would be helping doctors and scientists learn more about the best ways to treat COPD, especially for those who also have other health risks. This could lead to better treatments for many people with COPD in the future.
Key takeaways
- This study is for people with COPD who are at risk of heart or lung issues.
- It tests a new 3-in-1 inhaler against a standard 2-in-1 inhaler.
- The goal is to see if the new inhaler improves heart and lung health.
- Participation involves using an inhaler twice daily and attending regular check-ups.
- You won't know which inhaler you're using, and you can leave at any time.
Who may be eligible?
To be considered for this study, you need to be between 40 and 80 years old. You must have a confirmed diagnosis of COPD. You should also have a history of smoking for at least 10 'pack-years', which means how much you've smoked over your lifetime. If you've quit smoking, you need to have stopped at least six months before starting the study.
An important part of this study is that you must also be at a higher risk of heart or lung problems. This could mean you already have a heart condition, or you have risk factors like high blood pressure, diabetes, kidney disease, high cholesterol, or obesity. The study will also check your blood for a certain type of white blood cell, called eosinophils, and your score on a questionnaire about your COPD symptoms must be 10 or higher.
There are also reasons why you might not be able to join. For example, if you've been diagnosed with asthma in the last five years, or if you had childhood asthma that has continued into adulthood, you would not be eligible. The medical team will check all these details to see if this study is right for you.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you between 40 and 80 years old?
- Do you have a diagnosis of COPD?
- Have you smoked for at least 10 'pack-years' in your lifetime?
- Do you have a higher risk of heart or other lung problems?
- Can you use an inhaler correctly?
What does participation involve?
If you join this study, it will run for quite a long time, potentially several years, because researchers need to see how the inhalers affect your health over time. You'll use either the new 'triple therapy' inhaler or the 'dual therapy' inhaler twice a day. You won't know which one you're receiving, and neither will your local study doctor – this is called a 'double-blind' study and helps ensure the results are unbiased.
You will have regular appointments at the study clinic or virtual visits, as decided by the study team. During these visits, the team will check how your lungs are working, measure your blood pressure, and take blood samples. They'll also ask you questions about your health and any symptoms you might be experiencing. It's really important that you can reliably use an inhaler correctly and are willing to follow all the study instructions regarding your medications and visits.
Potential risks and benefits
Locations (920)
- Research SiteVerified postcodeAthens, United States· Terminated
- Research SiteVerified postcodeCullman, United States· Recruiting
- Research SiteVerified postcodeFairhope, United States· Terminated
- Research SiteVerified postcodeHuntsville, United States· Terminated
- Research SiteVerified postcodeMobile, United States· Recruiting
- Research SiteVerified postcodeSheffield, United States· Withdrawn
- Research SiteVerified postcodeGilbert, United States· Recruiting
- Research SiteVerified postcodeGlendale, United States· Withdrawn
- Research SiteVerified postcodeMesa, United States· Recruiting
- Research SiteVerified postcodeMesa, United States· Recruiting
- Research SiteVerified postcodePhoenix, United States· Terminated
- Research SiteVerified postcodeTempe, United States· Suspended
Common questions
What is COPD?
COPD stands for Chronic Obstructive Pulmonary Disease, which is a common lung condition that causes breathing difficulties.
What is a 'triple therapy' inhaler?
It's an inhaler that contains three different kinds of medicines to help manage your breathing and lung health.
Will I know which inhaler I'm getting?
No, neither you nor the study team will know which inhaler you are receiving. This helps make the study results fair.
How long will the study last?
The study is designed to follow participants for a longer period, possibly several years, to see the long-term effects of the treatments.
Can I stop participating in the study if I change my mind?
Yes, you can leave the study at any time, and it will not affect your regular medical care.
How to find out more
AstraZeneca Clinical Study Information Center
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.